Heart failure & cardiomyopathiesSecondary analysis
Association Between Body Mass Index and Clinical Outcomes in Patients with Acute Myocardial Infarction and Reduced Systolic Function: Analysis of PARADISE-MI Trial Data
- Secondary analysis of the PARADISE-MI randomised trial
Authors' conclusion
In AMI with AHF patients, the relationship between BMI and the primary composite outcome is non-linear, with the lowest event rates observed in overweight individuals. Outcomes and safety profiles for ARNI and ACE-I treatments were similar across BMI subgroups.
Study context
- Population
- Patients with acute myocardial infarction (AMI) and pulmonary congestion and/or LVEF ≤40%, with available baseline body mass index (BMI)6 WHO BMI subgroups
- Participants
- 5,589 patients
- Comparison
- WHO BMI categories; Angiotensin receptor-neprilysin inhibitor (ARNI) vs ACEi by BMI
- Primary endpoint
- CV death, heart failure (HF) hospitalization or outpatient symptomatic HF episodes
Primary result
As reported in the abstract
Overweight
6.2/100 patient-years
BMI <18.5 kg/m²
8.4/100 patient-years
BMI >40 kg/m²
9.7/100 patient-years
- No significant interaction between BMI and ARNI vs ACEi treatment effect
- P = 0.73
Safety
Adverse events and serious adverse events
- No significant differences across BMI subgroups
Original publication
Association Between Body Mass Index and Clinical Outcomes in Patients with Acute Myocardial Infarction and Reduced Systolic Function: Analysis of PARADISE-MI Trial Data. Eur J Heart Fail. Published 18 December 2024. doi:10.1002/ejhf.3542
Summarised from the published abstract; every number is checked against it